Patents Examined by John Edward Tarcza
  • Patent number: 4920055
    Abstract: Disclosed is a process for converting alcohols to aldehydes and hydrogen peroxide through the use of a methanol oxidase enzyme. The process involves introducing a lower alkyl or lower alkylene alcohol, such as methanol, ethanol, or allyl alcohol, as an aqueous solution into a reaction zone. Methanol oxidase enzyme that is stable in methanol concentrations of at least 0.5% and formaldehyde concentrations of at least 1.0% is also introduced into the reaction zone, which is maintained at an elevated pressure in contact with an oxygen-containing gas. The preferred methanol oxidase enzyme has the properties of the methanol oxidase enzyme produced by Hansenula polymorpha ATCC 34438. Both batchwise and continuous processes are disclosed. Also disclosed is a process in which a catalase is present in the reaction zone to decompose hydrogen peroxide as it is formed, so that the net reaction is the conversion of alcohol to aldehyde.
    Type: Grant
    Filed: February 4, 1986
    Date of Patent: April 24, 1990
    Assignee: American Biogenetics Corporation
    Inventors: Dane A. Hoiberg, G. Wesley Hatfield, Harris S. Moyed, Janice A. Sharp
  • Patent number: 4912039
    Abstract: A method for isolating a cDNA specific for P-glycoprotein is disclosed. The P-glycoprotein is the determinant in the multidrug resistance phenotype exhibited by living cells. The nucleic acid equivalent of the cDNA may be cloned in a recombinant plasmid or phage. The cDNA may also be used as a probe in determining multidrug resistance in cells. The DNA molecules specific for the P-glycoprotein is in the form of a gene family where various members of the gene family are amplified to varying degrees in multidrug resistant cells from various sources.
    Type: Grant
    Filed: September 10, 1985
    Date of Patent: March 27, 1990
    Assignee: HSC Research Development Corporation
    Inventor: John R. Riordan
  • Patent number: 4904596
    Abstract: A hybridoma cell line (ATCC No. HB 8873) secreting a monoclonal IgM antibody (FH6) directed to a fucoganglioside, 6B, which accumulates in human colonic adenocarcinoma but is absent in normal colonic mucosa. The structure of the 6B ganglioside to which the antibody FH6 is directed is as follows: ##STR1## The hybridoma secreting the antibody FH6 was selected by reactivity of the FH6 antibody with the 6B ganglioside (VI.sup.3 NeuAcV.sup.3 III.sup.3 Fuc.sub.2 nLc.sub.6) and lack of reactivity with other glycolipids, including glycolipids having closely related structures, such as sialosyllactoneotetraosylceramide (IV.sup.3 NeuAcnLc.sub.4), sialosyllactofucopentaosy(III)ceramide (IV.sup.3 NeuAcIII.sup.3 FucnLc.sub.4), sialosyllactofucopentaosy(II)ceramide (sialosyl-Le.sup.a glycolipid; IV.sup.3 NeuAcIII.sup.4 FucLc.sub.4), and 6C fucoganglioside (sialosyl 2.fwdarw.6 fucoganglioside; VI.sup.6 NeuAcIII.sup.3 FucnLc.sub.6).
    Type: Grant
    Filed: August 7, 1985
    Date of Patent: February 27, 1990
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Sen-itiroh Hakomori
  • Patent number: 4892829
    Abstract: Using a serum-free defined medium, a human cell line, NCI-H929, was established from a malignant effusion occuring in a patient with IgAk myeloma. The cultured cells have the morphologic, ultrastructural, biochemical, immunologic and cytochemical features of plasma cells. The cells have rearranged alpha and kappa genes and synthesize and secrete very high amounts of IgAk (>80 .mu.g/10.sup.6 cells/24 hr). The cells express surface immunoglobulin (alpha and kappa), the plasma cell antigen PCA-1, the transferrin receptor (T9) and T10, but lack antigens associated with earlier stages of B cell development (HLA-DR, B1, B2, B4, CALLA), as well as other leukocyte-macrophage antigens and Epstein-Barr virus nuclear antigen. While the tumor cells were predominantly near-diploid, the cultured cells are predominantly near-tetraploid with six copies of chromosome 8, four to six of which have an 8q+ abnormality.
    Type: Grant
    Filed: April 22, 1986
    Date of Patent: January 9, 1990
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Adi F. Gazdar, Herbert K. Oie
  • Patent number: 4891320
    Abstract: A process for degrading environmentally persistent organic pollutant compounds by reacting those pollutant compounds with fungal enzymes containing a lignin-degrading enzyme and hydrogen peroxide. This reaction preferably takes place under aerobic conditions such that the organic pollutant compounds are degraded. Using the present invention, degradation to carbon dioxide and water is possible. Alternatively, the reaction may be halted to leave desirable reaction intermediates.The enzyme and hydrogen peroxide system of the present invention is found to be ideal for degrading various types of orgaic pollutants. Moreover, the reaction system is nonspecific. As a result, only a single type of fungus or fungus-generated enzyme system is required in order to degrade a wide spectrum of pollutants.One embodiment of the present invention relates to a preferred process where the enzyme (peroxidase) and hydrogen peroxide are provided by a lignin-degrading fungi or fungi mixed with the pollutant organic compound.
    Type: Grant
    Filed: April 19, 1988
    Date of Patent: January 2, 1990
    Assignee: Utah State University Foundation
    Inventors: Steven D. Aust, John A. Bumpus, Ming Tien
  • Patent number: 4891317
    Abstract: A method of producing cellulose of amorphous character by subjecting cellulose-producing organisms to a magnetic field substantially greater than 0.5 gauss and preferably at least about 500 gauss. The cellulose produced in the presence of a magnetic field is of an amorphous nature with increased water absorptivity and decreased crystallinity.
    Type: Grant
    Filed: April 3, 1985
    Date of Patent: January 2, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: R. Malcolm Brown, Jr., Debra S. Brown, Michael R. Gretz
  • Patent number: 4861706
    Abstract: A quantitative assay for HAV comprises infecting at a temperature of from about to about C. a cell sheet with a dilution series of hepatitis A virus and then adding Newcastle disease virus (NDV) to the infected cell sheet and incubating the infected cell sheet in the presence of NDV at an elevated temperature for a time sufficient to permit a cytopathic effect (CPE) to become manifest, this time typically being at least about 4 days and preferably about 5 days. At an incubation temperature of from about to about C. the absence of CPE indicates the presence of HAV and the presence of CPE indicates the absence of HAV. At an incubation temperature of from about to about C. the absence of CPE indicates the absence of HAV and the presence of CPE indicates the presence of HAV.
    Type: Grant
    Filed: April 29, 1986
    Date of Patent: August 29, 1989
    Assignee: Merck & Co., Inc.
    Inventors: William M. Hurni, William J. Miller, William J. McAleer
  • Patent number: 4840934
    Abstract: Therapeutic methods and compositions using TCGF from HSB-2-ERICR cells and its mutants are disclosed.
    Type: Grant
    Filed: October 31, 1986
    Date of Patent: June 20, 1989
    Assignee: Eleanor Roosevelt Institute for Cancer Research, Inc.
    Inventor: David W. Anderson
  • Patent number: 4826766
    Abstract: This invention relates to a process for producing a desired alpha-amino acid, AA.sub.d, or a derivative thereof. The process comprises:(a) reacting a first alpha-amino acid, AA.sub.NH.sbsb.2 ; a first alpha-keto acid, KA.sub.t ; a second alpha-keto acid, KA.sub.pre ; a first transaminase enzyme and a second transaminase enzyme to produce (i) the desired alpha-amino acid, AA.sub.d and (ii) a third alpha-keto acid, ; and(b) removing from the other keto acids, amino acids and enzymes wherein AA.sub.d and KA.sub.pre, AA.sub.t and KA.sub.t, and AA.sub.NH.sbsb.2 and are interconvertible, respectively, by amino group transfer. The first transaminase efficiently catalyzes reaction (i), but not reaction (ii) and the second transaminase efficiently catalyzes reaction (ii) but not reaction (i):AA.sub.NH.sbsb.2 +KA.sub.t .revreaction.AA.sub.t (i)AA.sub.t +KA.sub.pre .revreaction.AA.sub.d +KA.sub.t (ii)In one embodiment KA.sub.
    Type: Grant
    Filed: September 23, 1985
    Date of Patent: May 2, 1989
    Assignee: Genetics Institute, Inc.
    Inventor: J. David Rozzell
  • Patent number: 4822735
    Abstract: A mutant T-cell line of HSB-2-ERICR which produces a T cell Growth Factor is disclosed. The Mutant cells are sensitive to HAT Medium.
    Type: Grant
    Filed: October 31, 1986
    Date of Patent: April 18, 1989
    Assignee: Eleanor Roosevelt Institute for Cancer Research, Inc.
    Inventor: David W. Anderson
  • Patent number: 4822734
    Abstract: Methods are disclosed for improving the efficiency of elicitation of monoclonal antibodies to glycoprotein antigens and tumor-associated antigens, and for inducing the production of IgG class monoclonal antibodies, in particular the IgG.sub.3 subclass. The methods involve the use of a lectin/extract immunogen to stimulate the production of the desired monoclonal antibodies.
    Type: Grant
    Filed: September 6, 1985
    Date of Patent: April 18, 1989
    Assignee: NeoRx Corporation
    Inventors: Alton C. Morgan, Jr., Robert McIntyre, Clive S. Woodhouse, Paul G. Abrams
  • Patent number: 4808532
    Abstract: Substantially genetically stable continuous human cell lines derived from normal human mammary epithelial cells (HMEC) and processes for making and using the same. In a preferred embodiment, the cell lines are derived by treating normal human mammary epithelial tissue with a chemical carcinogen such as benzo[a]pyrene. The novel cell lines serve as useful substrates for elucidating the potential effects of a number of toxins, carcinogens and mutagens as well as of the addition of exogenous genetic material. The autogenic parent cells from which the cell lines are derived serve as convenient control samples for testing. The cell lines are not neoplastically transformed, although they have acquired several properties which distinguish them from their normal progenitors.
    Type: Grant
    Filed: July 1, 1985
    Date of Patent: February 28, 1989
    Assignee: The United States of America as represented by the United States Department of Energy
    Inventor: Martha R. Stampfer
  • Patent number: 4806476
    Abstract: Cell fusion is induced between tumor cells that do not secrete a desired protein and mammalian cells or microcells derived from mammalian cells which secrete the desired protein, by substantially removing at least calcium ions to destabilize the cell membranes, adding a fusogen to the destabilized cells, and then adding back polyvalent cations.
    Type: Grant
    Filed: August 13, 1985
    Date of Patent: February 21, 1989
    Assignee: Lovelace Medical Foundation
    Inventors: Teresa Coons, Barry Avner
  • Patent number: 4804627
    Abstract: A method of growing cells, particularly cells transformed by Epstein Barr Virus, in agarose is disclosed. At least one of the agarose layers has human fibroblast cells suspended therein and another layer has irradiated fibroblasts and the particular growing cells suspended therein.
    Type: Grant
    Filed: May 9, 1985
    Date of Patent: February 14, 1989
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ulrich Hammerling, Slawomir Kosinski
  • Patent number: 4801690
    Abstract: A lectin derived from the pili of piliated organisms, said lectin being non-covalently bindable to the pilus rod protein of said pili and separable therefrom by the action of aqueous sodium dodecyl sulfate, possessing a single binding site for binding to mammalian erythrocyte ghosts.
    Type: Grant
    Filed: March 24, 1986
    Date of Patent: January 31, 1989
    Assignee: Bactex, Inc.
    Inventors: Charles C. Brinton, Jr., Mark Hanson
  • Patent number: 4800158
    Abstract: A method for degrading linalool using Pseudomonas strains is described. Also described are novel Pseudomonas putida strains which degrade linalool and in some instances geraniol and citronellol. A method for producing 6-methyl-5-heptene-2-one using certain novel strains is also described.
    Type: Grant
    Filed: March 20, 1986
    Date of Patent: January 24, 1989
    Assignee: Microlife Technics, Inc.
    Inventor: Peter A. Vandenbergh
  • Patent number: 4769321
    Abstract: Enzymatic assays are described which enable the detection of inter alia enzymes, cofactors and substrates in small quantity with the ability to produce a visually detectable change.
    Type: Grant
    Filed: April 21, 1986
    Date of Patent: September 6, 1988
    Inventor: Colin H. Self
  • Patent number: 4760025
    Abstract: A cloned subtilisin gene has been modified at specific sites to cause amino acid substitutions at certain spots in the enzyme. The modified enzyme, preferably produced by Bacillus, is useful in combination with detergents.
    Type: Grant
    Filed: May 29, 1984
    Date of Patent: July 26, 1988
    Assignee: Genencor, Inc.
    Inventors: David A. Estell, James A. Wells
  • Patent number: 4758514
    Abstract: 2-keto-L-gluonic acid (2-KLG) is prepared from 2,5-diketo-D-gluconic acid (2,5-DKG) using a microorganism containing the enzyme 2,5-DKG reductase produced by an expression plasmid encoding a gene for the enzyme. The product, 2-KLG is a precursor for the synthesis of ascorbic acid (vitamin C).
    Type: Grant
    Filed: June 14, 1984
    Date of Patent: July 19, 1988
    Assignee: Genentech, Inc.
    Inventors: David R. Light, William H. Rastetter
  • Patent number: 4752575
    Abstract: Two lymphotoxins are disclosed which are effective in mediating growth of malignant cell lines. The two lymphotoxins are designated as LT-2 and LT-3. A method for producing LT-2 and LT-3 is disclosed in which HUT-102 cells are stimulated with 4 Beta Phorbal 12-Myristate 13-Acetate (PMA).
    Type: Grant
    Filed: November 26, 1984
    Date of Patent: June 21, 1988
    Assignee: The Regents of the University of California
    Inventors: Gale A. Granger, Robert S. Yamamoto